Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas
暂无分享,去创建一个
A. Naing | A. Tsimberidou | Junsheng Ma | V. Subbiah | B. Stephen | S. Fu | M. Habra | C. Jimenez | D. Milton | Mingxuan Xu | F. Akhmedzhanov | A. Zarifa | Jordi Rodon Anhert
[1] P. Dahia,et al. HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: Metastatic pheochromocytomas and paragangliomas: proceedings of the MEN2019 workshop , 2020, Endocrine-Related Cancer.
[2] C. Jimenez,et al. Antiangiogenic therapies for pheochromocytoma and paraganglioma. , 2020, Endocrine-related cancer.
[3] R. Wendt,et al. High-specific-activity iodine 131 metaiodobenzylguanidine for the treatment of metastatic pheochromocytoma or paraganglioma: a novel therapy for an orphan disease. , 2020, Current opinion in endocrinology, diabetes, and obesity.
[4] R. Simon,et al. Phase 2 study of pembrolizumab in patients with advanced rare cancers , 2020, Journal for ImmunoTherapy of Cancer.
[5] C. Jimenez,et al. Metastatic pheochromocytoma and paraganglioma: Management of endocrine manifestations, surgery and ablative procedures, and systemic therapies. , 2020, Best practice & research. Clinical endocrinology & metabolism.
[6] P. Dahia,et al. Metastatic pheochromocytoma and paraganglioma: proceedings of the MEN2019 workshop. , 2020, Endocrine-related cancer.
[7] A. Dimberg,et al. Tumor angiogenesis: causes, consequences, challenges and opportunities , 2019, Cellular and Molecular Life Sciences.
[8] V. Patel,et al. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors , 2019, Journal of Immunotherapy for Cancer.
[9] W. Erwin,et al. Targeted Radionuclide Therapy for Patients with Metastatic Pheochromocytoma and Paraganglioma: From Low-Specific-Activity to High-Specific-Activity Iodine-131 Metaiodobenzylguanidine , 2019, Cancers.
[10] S. Asa,et al. A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial , 2019, British Journal of Cancer.
[11] B. Khoo,et al. Peptide Receptor Radionuclide Therapy as a Novel Treatment for Metastatic and Invasive Phaeochromocytoma and Paraganglioma , 2019, Neuroendocrinology.
[12] G. Linette,et al. A Single Dose of Neoadjuvant PD-1 Blockade Predicts Clinical Outcomes in Resectable Melanoma , 2019, Nature Medicine.
[13] N. Stambler,et al. Efficacy and Safety of High-Specific-Activity 131I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma , 2018, The Journal of Nuclear Medicine.
[14] C. Jimenez. Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer , 2018, Front. Endocrinol..
[15] B. Helmink,et al. The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. , 2018, Cancer cell.
[16] M. Sawyer,et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] E. Le Chatelier,et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients , 2018, Science.
[18] D. Schroeder,et al. Perioperative outcomes of syndromic paraganglioma and pheochromocytoma resection in patients with von Hippel‐Lindau disease, multiple endocrine neoplasia type 2, or neurofibromatosis type 1 , 2017, Surgery.
[19] W. Young,et al. Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years , 2017, The Journal of clinical endocrinology and metabolism.
[20] R. Dina,et al. Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: Relationship with the hypoxic response, immune evasion and malignant behavior , 2017, Oncoimmunology.
[21] V. Suman,et al. Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma , 2017, Endocrine.
[22] Ludmila V. Danilova,et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.
[23] A. Lam. Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours , 2017, Endocrine Pathology.
[24] J. Luke,et al. Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma , 2016, Proceedings of the National Academy of Sciences.
[25] Shouhao Zhou,et al. Constipation: an overlooked, unmanaged symptom of patients with pheochromocytoma and sympathetic paraganglioma. , 2015, European journal of endocrinology.
[26] J. Lunceford,et al. Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.
[27] R. Baum,et al. Peptide receptor radionuclide therapy with 90Y/177Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours) , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[28] O. Dekkers,et al. Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta‐analysis , 2014, Clinical endocrinology.
[29] P. Dahia. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity , 2014, Nature Reviews Cancer.
[30] A. Tabarin,et al. One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. , 2013, The Journal of clinical endocrinology and metabolism.
[31] E. Baudin,et al. Current and Future Treatments for Malignant Pheochromocytoma and Sympathetic Paraganglioma , 2013, Current Oncology Reports.
[32] M. Hofmann,et al. Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma. , 2013, The Journal of clinical endocrinology and metabolism.
[33] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[34] Shreyaskumar R Patel,et al. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra‐adrenal paragangliomas , 2012, Cancer.
[35] Lei Feng,et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. , 2011, The Journal of clinical endocrinology and metabolism.
[36] R. Hawkins,et al. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] F. Forrer,et al. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. , 2008, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[38] E. Krenning,et al. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[39] Sandro Santagata,et al. A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas , 2005, PLoS genetics.
[40] P. Vaupel,et al. Hypoxia-/HIF-1α-Driven Factors of the Tumor Microenvironment Impeding Antitumor Immune Responses and Promoting Malignant Progression. , 2018, Advances in experimental medicine and biology.
[41] Andrew L. Kung,et al. A HIF1-alpha Regulatory Loop Links Hypoxiaand Mitochondrial Signals in Pheochromocytomas , 2005 .